Galvanize Therapeutics raises $130M Series D to scale PEF ablation

Galvanize Therapeutics raises $130M Series D to scale PEF ablation

Latest Medtech News


Galvanize Therapeutics, a Redwood City, California, company developing pulsed electric field (PEF) ablation, has closed an oversubscribed $130 million Series D led by HealthQuest Capital. Olympus Innovation Ventures and Braidwell LP joined as new investors, and existing backers including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Fidelity and T. Rowe Price also took part. HealthQuest’s Dr. Garheng Kong will join the board.

As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.

The money will fund continued commercial expansion of the Aliya PEF system, more clinical evidence, advancement of RheOx therapy for chronic bronchitis, and development of next-generation PEF platforms. Over the past year Galvanize received FDA clearance and launched the Aliya EX Generator, passed 4,000 procedures, enrolled more than 300 patients in its PROPEL registry, and contributed to more than 40 peer-reviewed publications on PEF.

Aliya is 510(k)-cleared for surgical ablation of soft tissue. For Galvanize, the round pairs growth capital with an evidence program the company is building alongside its commercial rollout. CEO Doug Godshall called it “an important inflection point for Galvanize,” and said the company aims to broaden PEF’s role across oncology and chronic disease.

For the broader MedTech space, the round adds to investment in pulsed electric field technology beyond cardiac ablation, where PEF is better known.

Go Back

We'd love to hear what you're building